Literature DB >> 24859527

Ab initio molecular simulations for proposing novel peptide inhibitors blocking the ligand-binding pocket of urokinase receptor.

Tatsuroh Mizushima1, Takuya Sugimoto, Tomoyo Kasumi, Kohta Araki, Hiroshi Kobayashi, Noriyuki Kurita.   

Abstract

Recent biochemical experiments have revealed that a variety of proteases play important roles in cancer invasion and metastasis. Among these proteases, urokinase-type plasminogen activator (uPA) is particularly important, since its specific binding to the receptor (uPAR) existing on the surface of a cancer cell is considered to be a trigger for cancer invasion. It is thus expected that the blocking of the binding can inhibit cancer invasion in the cancer patients and improve their prognosis dramatically. To develop a potent inhibitor for the binding, many types of peptides of amino acids were produced and their effect on the cancer invasion was investigated in the previous biochemical experiments. On the other hand, our previous ab initio molecular simulations have clarified that some amino acid residues of uPA play important roles in the specific binding between uPA and uPAR. In the present study, we propose some peptides composed of these important residues and investigate the specific interactions and the binding affinity between uPAR and the peptides at an electronic level, using ab initio molecular simulations. Base on the results simulated, we elucidate which peptide can bind more strongly to uPAR and propose a novel potent peptide which can inhibit the binding between uPAR and uPA efficiently.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24859527     DOI: 10.1007/s00894-014-2292-7

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  17 in total

1.  The kringle stabilizes urokinase binding to the urokinase receptor.

Authors:  Khalil Bdeir; Alice Kuo; Bruce S Sachais; Ann H Rux; Yasmina Bdeir; Andrew Mazar; Abd Al-Roof Higazi; Douglas B Cines
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

2.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions.

Authors:  Mats H M Olsson; Chresten R Søndergaard; Michal Rostkowski; Jan H Jensen
Journal:  J Chem Theory Comput       Date:  2011-01-06       Impact factor: 6.006

3.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

4.  The Amber biomolecular simulation programs.

Authors:  David A Case; Thomas E Cheatham; Tom Darden; Holger Gohlke; Ray Luo; Kenneth M Merz; Alexey Onufriev; Carlos Simmerling; Bing Wang; Robert J Woods
Journal:  J Comput Chem       Date:  2005-12       Impact factor: 3.376

5.  Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.

Authors:  Qing Huai; Aiwu Zhou; Lin Lin; Andrew P Mazar; Graham C Parry; Jennifer Callahan; David E Shaw; Bruce Furie; Barbara C Furie; Mingdong Huang
Journal:  Nat Struct Mol Biol       Date:  2008-03-23       Impact factor: 15.369

6.  The receptor-binding sequence of urokinase. A biological function for the growth-factor module of proteases.

Authors:  E Appella; E A Robinson; S J Ullrich; M P Stoppelli; A Corti; G Cassani; F Blasi
Journal:  J Biol Chem       Date:  1987-04-05       Impact factor: 5.157

7.  The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology.

Authors:  E A Baker; D J Leaper
Journal:  Eur J Cancer       Date:  2003-05       Impact factor: 9.162

8.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

9.  Urokinase-type plasminogen activator in colorectal cancer: relationship with clinicopathological features and patient outcome.

Authors:  M M Skelly; A Troy; M J Duffy; H E Mulcahy; C Duggan; T G Connell; D P O'Donoghue; K Sheahan
Journal:  Clin Cancer Res       Date:  1997-10       Impact factor: 12.531

10.  Ab initio fragment molecular orbital study of molecular interactions in liganded retinoid X receptor: specification of residues associated with ligand inducible information transmission.

Authors:  Mika Ito; Kaori Fukuzawa; Takeshi Ishikawa; Yuji Mochizuki; Tatsuya Nakano; Shigenori Tanaka
Journal:  J Phys Chem B       Date:  2008-08-27       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.